CClinicalTrials.gg
CompletedNCT04449978Updated Dec 17, 2024

TARGet Kids! COVID-19 Study of Children and Families

An observational study in Coronavirus, COVID-19 and Virus, sponsored by The Hospital for Sick Children. Completed at 2 sites in Canada. Open to participants aged 0 Years to 16 Years. Per ClinicalTrials.gov, last updated 2024-12-17.

Sponsored by The Hospital for Sick Children · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,145
Ages
0 Years to 16 Years
Sex
All
01

Study summary

The novel coronavirus (COVID-19) was declared a global pandemic in March 2020. Early research suggests that children are no more susceptible to COVID-19 infection than adults and that children with confirmed COVID-19 have generally presented with milder symptoms. However, the impact of COVID-19 among Canadian children remains unclear. The prevalence of COVID-19 in children in Canada is currently unknown and no published research exists regarding the risk factors of COVID-19 in children or its potential long-term health effects on physical health or development. Using TARGet Kids!, Canada's largest children's cohort study with over 11,000 children involved, the researchers will conduct a longitudinal observational study aimed to evaluate the cumulative incidence of COVID-19 in children and parents; differences among infected and uninfected children in terms of age, sex, and income; risk factors of COVID-19; and longer term health effects of COVID-19 among children. Given the rapid spread of COVID-19 and the unknown health effects of the virus in children, research must be conducted to determine the extent of infections of COVID-19 in children, disease severity, risk factors for infection, and how the virus affects children as they become older.

Read the detailed description

The novel coronavirus (COVID-19) was declared a global pandemic in March 2020. Early research has suggested that children may experience less severe clinical symptoms than adults, and infected children with minimal or no symptoms may be an underrecognized source of community disease transmission. COVID-19 infections in children were occurring very early in the epidemic but the impact of COVID-19 infection among children remains unclear. The number of COVID-19 infections in children and parents in Canada is unknown and studies have not evaluated the symptom severity of COVID-19 in children and parents, risk factors for infection and severe disease, and whether current preventive efforts are effective. Using TARGet Kids!, Canada's largest children's cohort study, the researchers will conduct an observational study to evaluate key epidemiological characteristics of COVID-19 among parents and children, as well as to determine the spectrum of disease severity, seroprevalence, risk factors for COVID-19 infection and severe disease, effectiveness of social isolation recommendations, risk to family members with a COVID-19 infected family member, and potential new strategies to prevent COVID-19 infection and minimize disease severity. Parents of 1082 existing TARGet Kids! participants will be asked to provide a nasal swab from themselves and their child during the pandemic in addition to a respiratory tract symptom checklist. Preventive efforts (e.g. social distancing), parent-reported illness, laboratory-confirmed infections and healthcare encounters (e.g. emergency department visits, hospitalizations and ICU care) will be measured. Children will subsequently be followed through the TARGet Kids! cohort study over the next 6 months and long term, with interim analyses at 3 months. By understanding every stage of COVID-19 infection from prevention to transmission in the community and home, to outpatient and hospital care utilization, the researchers will rapidly develop new interventions to prevent COVID-19 transmission and minimize disease severity among children and their families. Descriptive statistics will be used to determine the prevalence of COVID-19 in healthy children.

02

Conditions studied

  • Coronavirus
  • COVID-19
  • Virus
  • Family and Household
  • Infection Viral
03

In context

COVID-19

7,640 studies on the registry are indexed under COVID-19; 488 are open to participants now.

This study's enrollment of 1,145 is above the median of 261 across 3,136 observational studies indexed under COVID-19.

Browse COVID-19 studies →

Lead sponsor

The Hospital for Sick Children is the lead sponsor of 568 studies on the registry; 81 are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
0 Years to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This study will be a prospective longitudinal observational study embedded within the TARGet Kids! cohort study, an ongoing longitudinal observational study enrolling healthy age 0-5 years who receive primary healthcare and following them until adolescence and early adulthood.

Inclusion criteria

  • Families with existing participants of the TARGet Kids! cohort with children between the ages of 0-16 years.

Exclusion criteria

Exclusion Criteria:

  • Families who are not participating in the TARGet Kids! cohort or participating families with no children within the age of eligibility.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,145 participants (actual)
Patient registry
No
Biospecimen retention
Samples without dna
06

What researchers measure

Primary outcomes

  1. Cumulative Incidence of COVID-19

    To evaluate the cumulative incidence of laboratory-confirmed COVID-19 among healthy children and parents in Toronto, Canada

    Time frame: 12 months

Secondary outcomes

  1. Risk Factors for COVID-19

    To determine the risk factors for COVID-19 infection in children and parents to inform preventive interventions

    Time frame: 12 months

  2. Parent-reported probable case definition of COVID-19

    To determine the cumulative incidence of parent-reported probable case definition of COVID-19 among children and parents.

    Time frame: 12 months

  3. Dynamics of COVID-19

    To determine the dynamics of COVID-19 infection using a susceptible-infected-recovered (SIR) multi-state model.

    Time frame: 12 months

  4. Risk to family members

    To determine the risk to family members with a laboratory-confirmed COVID-19 infected family member.

    Time frame: 12 months

  5. Severity of COVID-19

    To determine the severity of laboratory-confirmed COVID-19 in healthy children and parents

    Time frame: 12 months

  6. Longer term effects of COVID-19 on physical health

    To determine the longer term effects of COVID-19 infection in healthy children and parents on physical health

    Time frame: 12 months

  7. Longer term effects of COVID-19 on mental health

    To determine the longer term effects of COVID-19 infection in healthy children and parents on mental health

    Time frame: 12 months

  8. Longer term effects of COVID-19 on child development

    To determine the longer term effects of COVID-19 infection in healthy children and parents on child development

    Time frame: 12 months

  9. Longer term effects of COVID-19 on family functioning

    To determine the longer term effects of COVID-19 infection in healthy children and parents on family functioning

    Time frame: 12 months

  10. Longer term effects of COVID-19 on health behaviours

    To determine the longer term effects of COVID-19 infection in healthy children and parents on health behaviours

    Time frame: 12 months

  11. Longer term effects of COVID-19 on healthcare utilization

    To determine the longer term effects of COVID-19 infection in healthy children and parents on healthcare utilization

    Time frame: 12 months

  12. Effects of preventive measures on infection

    To determine the effect of preventive measures on COVID-19 infection

    Time frame: 12 months

  13. Effects of preventive measures on physical health

    To determine the effect of preventive measures on physical health

    Time frame: 12 months

  14. Effects of preventive measures on mental health

    To determine the effect of preventive measures on mental health

    Time frame: 12 months

  15. Effects of preventive measures on child development

    To determine the effect of preventive measures on child development

    Time frame: 12 months

  16. Effects of preventive measures on family functioning

    To determine the effect of preventive measures on family functioning

    Time frame: 12 months

  17. Effects of preventive measures on health behaviours

    To determine the effect of preventive measures on health behaviours

    Time frame: 12 months

  18. Effects of preventive measures on healthcare utilization

    To determine the effect of preventive measures on healthcare utilization

    Time frame: 12 months

07

Study locations

2 sites
  • St Michael's Hospital
    Toronto, Ontario M5B 1W8, Canada
  • The Hospital for Sick Children
    Toronto, Ontario M5G 1X8, Canada
08

References and documents

Individual participant data

Plan to share: No — There is not a plan to make IPD available.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04449978
Lead sponsor
The Hospital for Sick Children
Collaborators
Unity Health Toronto
Responsible party
Catherine Birken (Senior Scientist, The Hospital for Sick Children) — Principal investigator
First posted
Jun 29, 2020
Start date
Apr 9, 2020
Primary completion
Dec 30, 2022
Completion
Dec 31, 2023
Last update
Dec 17, 2024

Study contacts

Catherine S Birken, MD
principal investigator · The Hospital for Sick Children

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion